Overview
Location
Canada, Ontario, Toronto
Employees
51-200
Total raised
$20M
Founded date
2019
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 16, 2024 | IONETIX: Cyclotron Company Raises Funding Led By Tees River And Lilly | IONETIX, a leading cyclotron technology innovator and isotope manufacturer for diagnostic and therapeutic applications, announced a round of funding. The investors included Eli Lilly and Company and existing shareholders led by Tees River L... |
| Mar 19, 2024 | AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition | AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers, plunking down $2 billion to acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therap... |
| Feb 1, 2022 | POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs | Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Is... |
| Jan 4, 2022 | POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development | INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announce... |
| Dec 1, 2021 | POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes | Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities Jonath... |
| Sep 23, 2021 | POINT Biopharma Global : Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC | 25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS, Indiana, Sept. 23, 2021 (GLOBE NEWSWIRE) -- ... |
| Sep 14, 2021 | POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive mCRPC | Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa Cambridge Mass. and Indianapolis, Ind., September 14, 2021 - Convergent Therapeutics Inc., a clinical stag... |
| Sep 14, 2021 | Convergent Therapeutics : and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer | CAMBRIDGE, Mass. and INDIANAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage radiopharmaceutical company, and POINT Biopharma Global Inc., (Nasdaq: PNT) ("POINT") a company accelerating the disc... |
| Aug 10, 2021 | POINT Biopharma Global : Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC | INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the completion of enrollm... |
Show more
Reviews 0
FAQ about POINT Biopharma
When was POINT Biopharma founded?
POINT Biopharma was founded in 2019.
How much funding has POINT Biopharma raised?
POINT Biopharma has raised $20M in total across 1 funding round.
What has the press written about POINT Biopharma?
Parsers VC has collected 15 articles mentioning POINT Biopharma, among them “IONETIX: Cyclotron Company Raises Funding Led By Tees River And Lilly” (Aug 16, 2024) and “AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition” (Mar 19, 2024).
Is POINT Biopharma still active?
Yes, POINT Biopharma is active; its latest activity on Parsers VC dates from Sep 19, 2024.